JP2005513059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513059A5 JP2005513059A5 JP2003552269A JP2003552269A JP2005513059A5 JP 2005513059 A5 JP2005513059 A5 JP 2005513059A5 JP 2003552269 A JP2003552269 A JP 2003552269A JP 2003552269 A JP2003552269 A JP 2003552269A JP 2005513059 A5 JP2005513059 A5 JP 2005513059A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- pharmaceutical
- weight
- coated tablet
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims 34
- 239000003826 tablet Substances 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 9
- 239000013543 active substance Substances 0.000 claims 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 9
- 239000012876 carrier material Substances 0.000 claims 7
- 239000011248 coating agent Substances 0.000 claims 7
- 238000000576 coating method Methods 0.000 claims 7
- 229920003168 pharmaceutical polymer Polymers 0.000 claims 7
- 241000283073 Equus caballus Species 0.000 claims 6
- 229940011871 estrogen Drugs 0.000 claims 6
- 239000000262 estrogen Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 235000010980 cellulose Nutrition 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 3
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 claims 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 claims 3
- 229960003399 estrone Drugs 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 229920000881 Modified starch Polymers 0.000 claims 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 235000019426 modified starch Nutrition 0.000 claims 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims 2
- 229920000193 polymethacrylate Polymers 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000001069 triethyl citrate Substances 0.000 claims 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 2
- 235000013769 triethyl citrate Nutrition 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 239000003831 antifriction material Substances 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 229940035811 conjugated estrogen Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000013563 matrix tablet Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000006082 mold release agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000009495 sugar coating Methods 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 238000009827 uniform distribution Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129830 | 2001-12-14 | ||
| EP01129830.4 | 2001-12-14 | ||
| PCT/EP2002/014103 WO2003051336A1 (de) | 2001-12-14 | 2002-12-12 | Matrix-filmtablette mit kontrollierter freisetzung von natürlichen gemischen konjugierter oestrogene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513059A JP2005513059A (ja) | 2005-05-12 |
| JP2005513059A5 true JP2005513059A5 (enExample) | 2006-01-19 |
| JP4695837B2 JP4695837B2 (ja) | 2011-06-08 |
Family
ID=8179548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552269A Expired - Fee Related JP4695837B2 (ja) | 2001-12-14 | 2002-12-12 | 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8268351B2 (enExample) |
| EP (1) | EP1465602B1 (enExample) |
| JP (1) | JP4695837B2 (enExample) |
| CN (1) | CN100542538C (enExample) |
| AR (1) | AR037760A1 (enExample) |
| AT (1) | ATE438384T1 (enExample) |
| AU (1) | AU2002361396B2 (enExample) |
| BR (1) | BR0215044A (enExample) |
| CA (1) | CA2470207C (enExample) |
| DE (1) | DE50213751D1 (enExample) |
| DK (1) | DK1465602T3 (enExample) |
| ES (1) | ES2328910T3 (enExample) |
| MX (1) | MXPA04005769A (enExample) |
| PL (1) | PL205739B1 (enExample) |
| PT (1) | PT1465602E (enExample) |
| SI (1) | SI1465602T1 (enExample) |
| TW (1) | TWI252111B (enExample) |
| WO (1) | WO2003051336A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7303763B2 (en) * | 2001-02-12 | 2007-12-04 | Watson Laboratories, Inc. | Compositions for conjugated estrogens and associated methods |
| ES2377729T3 (es) * | 2002-02-21 | 2012-03-30 | Valeant International (Barbados) Srl | Formulaciones de liberación modificada de al menos una forma de tramadol |
| US8323692B2 (en) | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| US6992075B2 (en) * | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| JP4521554B2 (ja) * | 2004-03-31 | 2010-08-11 | マイラン製薬株式会社 | シクロスポリン製剤 |
| DE102004035938A1 (de) * | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil |
| EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| JP5162141B2 (ja) * | 2007-02-20 | 2013-03-13 | エスエス製薬株式会社 | フィルムコーティング用組成物 |
| JP4864024B2 (ja) * | 2008-02-15 | 2012-01-25 | エスエス製薬株式会社 | 時限放出製剤 |
| US20090232897A1 (en) * | 2008-03-14 | 2009-09-17 | Bijayananda Sahoo | Pharmaceutical compositions comprising conjugated estrogens |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753767A (en) * | 1971-08-02 | 1973-08-21 | Colgate Palmolive Co | Method of sugar-coating tablets |
| DE3535536A1 (de) * | 1985-10-04 | 1987-04-09 | Lentia Gmbh | Verfahren zum gleichzeitigen trocknen und granulieren von extraktstoffen aus enteiweisstem kaelberblut |
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| EP0322020A1 (en) * | 1987-12-22 | 1989-06-28 | Akzo N.V. | Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis |
| HU9500322D0 (en) * | 1994-02-08 | 1995-03-28 | Solvay Deutschland | Process for separating estrogenes from the urine of mares with foal |
| US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| DE4429398C2 (de) * | 1994-08-09 | 1997-09-11 | Jenapharm Gmbh | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| CN1101683C (zh) * | 1996-08-30 | 2003-02-19 | 索尔瓦药物有限公司 | 由牝马尿获取雌激素的方法 |
| CN1101682C (zh) * | 1996-08-30 | 2003-02-19 | 索尔瓦药物有限公司 | 由牝马尿液获取雌激素的方法 |
| DK0923381T3 (da) | 1996-08-30 | 2004-05-10 | Solvay Pharm Gmbh | Fremgangsmåde til fremstilling af östrogener ud fra hoppeurin |
| ATE264110T1 (de) | 1996-08-30 | 2004-04-15 | Solvay Pharm Gmbh | Prozess zur gewinnung von oestrogenen aus stutenharn |
| AU8699298A (en) * | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| DE19845358A1 (de) * | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe |
| EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| DK1183014T3 (da) * | 1999-06-14 | 2004-02-09 | Cosmo Spa | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse |
| US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
-
2002
- 2002-11-29 TW TW091134751A patent/TWI252111B/zh not_active IP Right Cessation
- 2002-12-09 AR ARP020104765A patent/AR037760A1/es not_active Application Discontinuation
- 2002-12-12 JP JP2003552269A patent/JP4695837B2/ja not_active Expired - Fee Related
- 2002-12-12 ES ES02796612T patent/ES2328910T3/es not_active Expired - Lifetime
- 2002-12-12 CN CNB028262034A patent/CN100542538C/zh not_active Expired - Fee Related
- 2002-12-12 AU AU2002361396A patent/AU2002361396B2/en not_active Ceased
- 2002-12-12 MX MXPA04005769A patent/MXPA04005769A/es active IP Right Grant
- 2002-12-12 CA CA2470207A patent/CA2470207C/en not_active Expired - Fee Related
- 2002-12-12 EP EP02796612A patent/EP1465602B1/de not_active Expired - Lifetime
- 2002-12-12 BR BR0215044-1A patent/BR0215044A/pt active Search and Examination
- 2002-12-12 AT AT02796612T patent/ATE438384T1/de active
- 2002-12-12 PL PL369367A patent/PL205739B1/pl unknown
- 2002-12-12 PT PT02796612T patent/PT1465602E/pt unknown
- 2002-12-12 SI SI200230848T patent/SI1465602T1/sl unknown
- 2002-12-12 DE DE50213751T patent/DE50213751D1/de not_active Expired - Lifetime
- 2002-12-12 DK DK02796612T patent/DK1465602T3/da active
- 2002-12-12 WO PCT/EP2002/014103 patent/WO2003051336A1/de not_active Ceased
-
2004
- 2004-06-14 US US10/866,094 patent/US8268351B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4505059B2 (ja) | エチルセルローズ水性分散液で被覆した放出制御製剤 | |
| Remuñán-López et al. | Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery | |
| JP5000509B2 (ja) | 糖被覆物及び被覆方法 | |
| US5427798A (en) | Controlled sustained release tablets containing bupropion | |
| EP1929998A2 (en) | Controlled release solid dispersions of carvedilol | |
| JP2011503017A (ja) | ヒドロモルホン含有徐放性錠剤 | |
| KR101367814B1 (ko) | 위장체류 제제 및 이의 제조 방법 | |
| JP2005513059A5 (enExample) | ||
| EA026335B1 (ru) | Снижение флуктуаций опиоидов в крови | |
| TW200815032A (en) | Use of polyols to obtain stable polymorphous forms of rifaximin | |
| EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| O'Donnell et al. | Aqueous pseudolatex of zein for film coating of solid dosage forms | |
| CA2470207A1 (en) | Matrix film tablet with controlled release of natural mixtures of conjugated estrogens | |
| SI22849A (sl) | Ropinirolni pripravek | |
| RS51271B (sr) | Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid | |
| JP4280074B2 (ja) | マルチプルユニット型徐放性錠剤 | |
| WO2007021072A1 (en) | Metformin tablet with sustained release and method for preparing the same | |
| AU2005313262B2 (en) | Tablets for the sustained release of indapamide and preparation method thereof | |
| RU2025121C1 (ru) | Фармацевтическая гранулированная композиция и способ ее получения | |
| WO2005011682A1 (ja) | 経口徐放性錠剤 | |
| ES2219602T3 (es) | Composicion farmaceutica de liberacion controlada conteniendo bupropion hcl como principio activo. | |
| CN110693884A (zh) | 一种复方制剂缬沙坦氨氯地平片及其制备方法 | |
| RU2155038C1 (ru) | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения | |
| KR0169163B1 (ko) | 방출제어형 이프리플라본 부유정제 및 그의 제조방법 | |
| EP1510205B1 (en) | Universal controlled-release composition comprising xanthan gum and sodium alginate |